EMA will request more data on Raxone, delaying bid for label expansion

19 May 2017
2019_biotech_test_vial_discovery_big

Santhera Pharmaceuticals (SIX: SANN) says its bid to broaden the European label of Raxone (idebenone) has been delayed.

The Swiss drugmaker has applied to extend the marketable use of the drug, to include slowing loss of respiratory function in patients with Duchenne muscular dystrophy (DMD) who are currently not taking glucocorticoids.

Santhera says it is “now expecting to receive a request for supplementary information to further support the clinical relevance of our data,” and anticipates a decision in the third quarter of this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology